SEC Comment Letter 0000000000-23-003334 to Y-mAbs Therapeutics, Inc. (YMAB) (CIK 0001722964)
Y-mAbs Therapeutics, Inc. (YMAB) (CIK 0001722964)
Date: April 3, 2023 · CIK: 0001722964 · Accession: 0000000000-23-003334
AI Filing Summary & Sentiment
File numbers found in text: 333-271006
Letter
United States securities and exchange commission logo April 3, 2023 Thomas Gad Founder and President Y-mAbs Therapeutics, Inc. 230 Park Avenue Suite 3350 New York, NY 10169 Re:Y-mAbs Therapeutics, Inc. Registration Statement on Form S-3 Filed March 30, 2023 File No. 333-271006 Dear Thomas Gad: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Sarah K. Sellers, Esq.
Show Raw Text
United States securities and exchange commission logo
April 3, 2023
Thomas Gad
Founder and President
Y-mAbs Therapeutics, Inc.
230 Park Avenue
Suite 3350
New York, NY 10169
Re:Y-mAbs Therapeutics, Inc.
Registration Statement on Form S-3
Filed March 30, 2023
File No. 333-271006
Dear Thomas Gad:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Sarah K. Sellers, Esq.